Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for Hyperinflammation in COVID-19 Pneumonia
2020-001841-38Phase 3Active
- Sponsor
- Sociedad Española de Cardiología
- Start
- May 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of colchicine in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia, sponsored by Sociedad Española de Cardiología. Primary endpoint: Composite respiratory support or death outcome. Started May 2020; status: active.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001841-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001841-38.